These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26155391)

  • 1. PDL1 expression is an independent prognostic factor in localized GIST.
    Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
    Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
    Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
    Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
    de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of PDL1 expression in pancreatic cancer.
    Birnbaum DJ; Finetti P; Lopresti A; Gilabert M; Poizat F; Turrini O; Raoul JL; Delpero JR; Moutardier V; Birnbaum D; Mamessier E; Bertucci F
    Oncotarget; 2016 Nov; 7(44):71198-71210. PubMed ID: 27589570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Grade Index predicts postoperative clinical outcome of GIST.
    Bertucci F; Finetti P; Ostrowski J; Kim WK; Kim H; Pantaleo MA; Astolfi A; Polkowski M; Birnbaum D
    Br J Cancer; 2012 Oct; 107(8):1433-41. PubMed ID: 22929880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
    Wang YL; Gong Y; Lv Z; Li L; Yuan Y
    J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
    [No Abstract]   [Full Text] [Related]  

  • 7. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death ligand 1 expression in osteosarcoma.
    Shen JK; Cote GM; Choy E; Yang P; Harmon D; Schwab J; Nielsen GP; Chebib I; Ferrone S; Wang X; Wang Y; Mankin H; Hornicek FJ; Duan Z
    Cancer Immunol Res; 2014 Jul; 2(7):690-698. PubMed ID: 24866169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Billon E; Finetti P; Bertucci A; Niccoli P; Birnbaum D; Mamessier E; Bertucci F
    Oncoimmunology; 2019; 8(11):e1655362. PubMed ID: 31646101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
    Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
    Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
    Rusakiewicz S; Semeraro M; Sarabi M; Desbois M; Locher C; Mendez R; Vimond N; Concha A; Garrido F; Isambert N; Chaigneau L; Le Brun-Ly V; Dubreuil P; Cremer I; Caignard A; Poirier-Colame V; Chaba K; Flament C; Halama N; Jäger D; Eggermont A; Bonvalot S; Commo F; Terrier P; Opolon P; Emile JF; Coindre JM; Kroemer G; Chaput N; Le Cesne A; Blay JY; Zitvogel L
    Cancer Res; 2013 Jun; 73(12):3499-510. PubMed ID: 23592754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
    Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.
    Tabanelli V; Corsini C; Fiori S; Agostinelli C; Calleri A; Orecchioni S; Melle F; Motta G; Rotili A; Di Napoli A; Pileri SA
    Hum Pathol; 2019 Aug; 90():60-69. PubMed ID: 31125630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
    Paré L; Pascual T; Seguí E; Teixidó C; Gonzalez-Cao M; Galván P; Rodríguez A; González B; Cuatrecasas M; Pineda E; Torné A; Crespo G; Martin-Algarra S; Pérez-Ruiz E; Reig Ò; Viladot M; Font C; Adamo B; Vidal M; Gaba L; Muñoz M; Victoria I; Ruiz G; Viñolas N; Mellado B; Maurel J; Garcia-Corbacho J; Molina-Vila MÁ; Juan M; Llovet JM; Reguart N; Arance A; Prat A
    Ann Oncol; 2018 Oct; 29(10):2121-2128. PubMed ID: 30165419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma.
    Jlassi A; Rejaibi R; Manai M; Sahraoui G; Guerfali FZ; Charfi L; Mezlini A; Manai M; Mrad K; Doghri R
    Front Oncol; 2024; 14():1352053. PubMed ID: 38634058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.